How many clinical trials has LL-37 undergone?

LL-37 has 20 registered clinical trials across multiple indication areas including wound healing, infection, and inflammatory conditions. However, only a subset have published peer-reviewed results, limiting full transparency of outcomes.

Is LL-37 approved by the FDA or other regulatory agencies?

No. LL-37 is not approved by the FDA, EMA, or Health Canada. It remains a research compound. Grade B evidence indicates promising findings but insufficient evidence for regulatory licensing.

What does Grade B evidence mean for LL-37?

Grade B evidence reflects moderate-quality support: positive signals exist in well-designed trials, but sample sizes may be modest, heterogeneity is present, and larger confirmatory studies are needed before regulatory decisions.

Where is LL-37 research most promising?

Wound healing and antimicrobial resistance are the strongest evidence areas. Both have generated positive trial signals, though larger Phase 2/3 studies are needed to confirm efficacy and define optimal use.

Why hasn't LL-37 been approved as a therapy yet?

Key barriers include formulation stability (peptide degradation), publication gaps (many trials lack full results), heterogeneous trial design, and modest sample sizes. Larger confirmatory trials and improved manufacturing are prerequisites for regulatory review.

LL-37 Research Evidence: Clinical Trials & Studies

LL-37 is a research compound—specifically, an antimicrobial peptide derived from human cathelicidin—that has generated significant scientific interest over the past two decades. With 20 clinical trials registered and a Grade B evidence rating, LL-37 represents a moderately well-studied peptide candidate. The research landscape reveals promising preclinical data and early-stage human trials, though LL-37 remains a research compound without FDA, EMA, or Health Canada approval. This guide synthesizes the clinical trial evidence, key study findings, and identifies where the research gaps still lie.

The LL-37 Research Landscape

LL-37 (cathelicidin-related antimicrobial peptide) has been the subject of focused investigation since the late 1990s. Unlike established therapeutics, LL-37 occupies a unique position in the research pipeline: it has accumulated meaningful clinical evidence without progressing to regulatory approval. A systematic examination of registered trials shows 20 clinical investigations involving LL-37, spanning multiple indication areas.

The compound's mechanism centres on its role as an endogenous antimicrobial peptide. Research indicates that LL-37 functions through multiple pathways: direct bacterial and fungal killing, modulation of immune cell recruitment, and wound-healing stimulation. This multi-target profile distinguishes it from conventional antibiotics and makes it theoretically relevant to conditions ranging from infection to chronic inflammation.

Clinical Trial Evidence Grade: B

LL-37 carries a Grade B evidence rating, reflecting moderate-quality evidence with some limitations in trial design, participant numbers, or outcome standardization. Grade B does not mean the evidence is weak—it means the body of evidence is promising but not yet definitive. Key clinical outcomes from LL-37 trials have demonstrated efficacy signals in wound healing and antimicrobial contexts, though effect sizes and consistency across trials vary.

Grade B evidence typically indicates:

Positive findings in well-designed trials, but sample sizes may be modest
Some heterogeneity in outcomes across studies
Evidence sufficient to inform research priorities, but not yet regulatory approval
Need for larger confirmatory trials

This grading is consistent with LL-37's current status: a compound with genuine therapeutic potential that requires additional evidence generation before licensing agencies move it forward.

Key Research Areas & Trial Data

Wound Healing & Dermatology

A significant portion of LL-37 clinical work focuses on wound healing. Preclinical and early clinical evidence suggests that LL-37 promotes epithelialization and angiogenesis, two critical wound-healing processes. Studies in diabetic foot ulcers and chronic wounds have reported improvements in healing rate and time-to-closure, though larger randomized trials are needed to confirm efficacy in heterogeneous patient populations.

The dermatological interest extends to skin barrier function. LL-37 concentrations are reportedly dysregulated in inflammatory skin conditions, and preclinical data suggests topical LL-37 may restore barrier integrity. However, translation to licensed products has been limited by formulation challenges and manufacturing complexity.

Infection & Antimicrobial Resistance

Given the global antimicrobial resistance crisis, LL-37 has attracted attention as a potential alternative mechanism to conventional antibiotics. Research indicates that LL-37 can kill drug-resistant bacteria including MRSA and Pseudomonas aeruginosa, and does so through membrane disruption rather than enzymatic inhibition—a pathway where resistance mechanisms are theoretically slower to emerge.

Clinical trials in wound infection and respiratory infection contexts have been initiated, though published results remain limited. The challenge lies in delivery: LL-37 must reach target tissues in active form, and systemic administration may trigger immune responses or rapid degradation.

Immunomodulation & Inflammation

Beyond its direct antimicrobial properties, LL-37 acts as an immunomodulator. Animal studies demonstrate that LL-37 recruits and activates neutrophils and dendritic cells, bridging innate and adaptive immunity. This property has prompted investigation in contexts where immune dysregulation plays a pathogenic role.

Clinical trials examining LL-37 in chronic inflammatory conditions have yielded mixed results. Some trials suggest benefit in periodontal disease and oral mucositis, while others show modest or null effects. Heterogeneity in dosing, delivery route, and study population may explain inconsistency.

What the Research Shows: Strengths & Limitations

Strengths of the Evidence Base

Mechanistic clarity: LL-37's antimicrobial and immunomodulatory mechanisms are well-characterized in vitro and in animal models.
Consistent early signals: Multiple independent trials report positive trends, particularly in wound healing and antimicrobial contexts.
Safety profile: Across 20 registered trials, LL-37 has demonstrated acceptable tolerability at tested doses, with no major safety signals reported in published abstracts and summaries.
Natural origin: As an endogenous peptide, LL-37 faces lower inherent toxicity risk compared to synthetic small molecules.

Key Limitations & Gaps

Limited published detail: Many LL-37 trials remain unpublished or available only as conference abstracts. Full peer-reviewed manuscripts are sparse, complicating evidence synthesis and reproducibility assessment.
Heterogeneous endpoints: Clinical trials use varying primary and secondary outcomes, making direct comparison difficult. Standardized metrics (e.g., time-to-closure in wound trials) remain inconsistently applied.
Formulation challenges: LL-37 is a 37-amino-acid peptide subject to enzymatic degradation. Stable, bioavailable formulations are difficult to manufacture, which limits therapeutic reach and may explain why certain trials report null results despite positive preclinical data.
Sample sizes: Most published LL-37 trials are modest in scale (10–100 participants). Larger Phase 2 and Phase 3 studies are needed to establish efficacy in target populations.
Unclear dosing optimization: Across trials, LL-37 doses and administration routes vary widely. Dose-response studies are limited, leaving optimal therapeutic doses undefined.

Related compounds like ARA-290 and ACE-031 have faced similar challenges in bridging preclinical promise to clinical translation, underscoring the broader difficulty in moving peptide therapeutics from bench to bedside.

Research Evidence by Indication

Wound Healing: Grade B (Moderate Evidence)

Multiple trials support LL-37's role in accelerating wound closure and promoting granulation tissue. Effect sizes are moderate. Optimal patient populations and formulations remain to be defined.

Infection (Bacterial/Fungal): Grade B (Moderate Evidence)

Preclinical and early clinical data are encouraging, but human efficacy trials are limited in number and size. No Phase 3 infection trial has reported published results to date.

Chronic Inflammation & Periodontal Disease: Grade C (Emerging Evidence)

Some signals of benefit, but evidence is preliminary. Larger, well-designed trials are needed.

Other Indications (Respiratory, Systemic): Grade C–D (Limited Evidence)

Highly preliminary. Mechanistic rationale exists, but human data are sparse or absent.

The Path Forward: What's Next in LL-37 Research

For LL-37 to progress toward regulatory approval, several evidence gaps must be closed:

Large, multi-center Phase 2/3 trials: Confirmatory studies in well-defined populations with standardized endpoints are essential. A focus on wound healing or chronic infection seems most promising given current evidence.
Formulation optimization: Improved, stable formulations that minimize peptide degradation and enhance bioavailability are prerequisite to clinical translation.
Publication of trial data: Many registered trials lack published results. Dissemination of findings—positive or negative—is critical for evidence synthesis and scientific decision-making.
Mechanistic biomarkers: Identifying patient populations most likely to respond (e.g., via LL-37 baseline status, immune phenotyping) could enrich trial populations and improve trial efficiency.
Comparison with standards: Head-to-head trials versus current standard-of-care treatments (e.g., conventional wound dressings, antibiotics) would clarify clinical advantage.

LL-37 is not unique in this respect. Other peptide candidates, such as Abaloparatide (which achieved FDA approval in osteoporosis), have required extensive clinical evidence generation and formulation work before licensure. The peptide class, while mechanistically novel, faces inherent manufacturing and stability constraints that slow regulatory progress.

Where the Data Stands: A Synthesis

LL-37 research evidence is genuinely promising in specific contexts—particularly wound healing and antimicrobial applications—yet remains incomplete. The Grade B evidence rating reflects this reality: there is enough positive signal to justify continued investigation, but not enough certainty to support regulatory approval or clinical use outside trials.

The 20 registered clinical trials represent meaningful investment in this compound. However, publication bias and heterogeneity limit our ability to synthesize findings definitively. If key trials in wound healing or infection move to Phase 3 and report positive results, LL-37 could become a strong candidate for regulatory review. Conversely, if large confirmatory trials fail to replicate early signals, research interest may wane.

As of now, LL-37 remains a research compound of genuine scientific interest but without an established clinical role. Anyone tracking peptide therapeutics should expect further trial data and publications over the coming years—and watchful interpretation will be needed to determine whether LL-37 ultimately translates to approved therapy.

Why Evidence Grading Matters

Understanding evidence grades—such as LL-37's Grade B rating—is critical for consumers and researchers evaluating compound potential. Grade B evidence is not regulatory approval, nor is it marketing permission. It reflects the current scientific consensus: promising, but incomplete. This distinction between research evidence and clinical authorisation is essential when evaluating any research compound.

Compounds at similar evidence stages include Bacitracin in certain research contexts and Argireline in cosmetic and anti-aging research—both of which have accumulated meaningful data yet face regulatory or translational barriers.

LL-37 Research Evidence: What Clinical Trials & Studies Reveal